Hannah Valantine - 29 Dec 2021 Form 4/A - Amendment Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Hannah A. Valantine, M.D.
Issuer symbol
BBIO
Transactions as of
29 Dec 2021
Net transactions value
+$24,948
Form type
4/A - Amendment
Filing time
30 Jun 2025, 17:49:25 UTC
Date Of Original Report
03 Jan 2022
Previous filing
30 Jun 2025
Next filing
27 May 2022
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Valantine Hannah Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Hannah A. Valantine, M.D. 30 Jun 2025 0001855608

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Purchase $24,948 +1,752 +114% $14.24 3,294 29 Dec 2021 Direct
holding BBIO Common Stock 2,687 29 Dec 2021 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.